A new combination chemotherapy(VEPA) was applied to 9 patients with advanced and/or non-resectable primary gastric lymphoma. Among 6 patients with measurable disease, there were 3 (50%) complete responses and 1 (17%) incomplete response. None of 3 patients with lymph node and/or anastomosis involvements at the gastrectomy have relapsed after 13 months to 32 months. Complications during chemotherapy with VEPA were mild myelosuppression and gastrointestinal disturbances, and severe alopecia. Only one paralytic ileus with vincristine occurred, but no cardiotoxicities with adriamycin were observed. This study indicates that VEPA therapy is effective in the patients with primary gastric lymphoma.

Adult↗

PubMed1982

[Clinical values of cytological evaluation of pleural and peritoneal fluids].

We reviewed retrospectively the data obtained from our Department of Clinical Cytology, National Cancer Center in the period of 1964 and 1981, which clearly showed an increasing clinical importance of cytological evaluation of pleural and peritoneal fluids for greater diagnostic efficacy. For example, existence of tumor cells could predict a possibility of local infiltration. Cytological examination could also provide significant information for planning the treatment protocols prior to the initiation of the treatment as well as for predicting efficacy of the treatment using characteristics in particular of lymphocytes, phagocytes and granulocytes. Furthermore, accurate interpretation of cytological examination of pleural and peritoneal fluids seem to be clinically highly suggestive for diagnostic efficacy and also could be a helpful means for evaluation of cancer therapy.

Cytodiagnosis↗

PubMed1982

[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma].

The VM*P combination chemotherapy was administered to 13 patients with advanced (Stage III and IV) non-Hodgkin's lymphoma refractory to previous multiagent chemotherapy including cyclophosphamide (EX) and/or adriamycin (ADM). 1) Complete response was obtained in two patients with diffuse histiocytic lymphoma and one patient with diffuse undifferentiated (Burkitt type) lymphoma, and a response rate was 46.2%. 2) Tumor regression in responders was recognized within one week after administration of VM*P, but the duration of response was only 7(2-17) weeks in median (range). 3) Positive correlation was not seen between responsibility and dose of vincristine or methotrexate (MTX), but complete responders were obtained with only over 30 mg/dose of MTX. 4) In spite of resistant cases against EX and/or ADM, complete responders were obtained with VM*P therapy. Clinically, it was shown that cross resistance was minimal among MTX, EX and ADM. 5) Major side effects of VM*P therapy were myelosuppression (75%), hepatotoxicity (46%), and severe infection (23%). Neurotoxicity and nephrotoxicity were rare.

Adult↗

PubMed1981